Qin Zhen, Tang Lisha, Huang Qianyi, Chen Yan, Zhong Wei, Tang Xiangqi
Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Eur J Clin Invest. 2021 Aug;51(8):e13558. doi: 10.1111/eci.13558. Epub 2021 Jun 10.
To investigate the correlation between serum asymmetric dimethylarginine (ADMA) and the risk of ischaemic stroke and carotid atherosclerosis in adults.
We systematically searched PubMed, EMBASE, Web of Science and other databases for relevant studies on serum ADMA and ischaemic stroke or carotid atherosclerosis, which were published from December 1980 to December 2019. The quality of the included studies was evaluated according to the Cochrane system evaluation standard. The difference in serum ADMA level between ischaemic stroke and control group was selected as the effect size (standardized mean difference, SMD). The pooled analysis was performed using Review Manager (V.5.3).
According to the selection criteria, thirteen studies were included in the meta-analysis after screening. Nine studies compared ADMA levels between the ischaemic stroke group and healthy control group, involving a total of 1315 and 880 subjects in the two groups, respectively. Pooled effect sizes were calculated using the random-effects model due to the high heterogeneity (I = 93%, P < .00001). The level of serum ADMA in patients with ischaemic stroke was significantly higher than that in healthy people (SDM = 0.69, 95% CI [0.32, 1.06], P = .0002). Seven of the thirteen articles compared ADMA levels between the carotid arteriosclerosis group and the healthy control group, with 559 and 330 subjects in the two groups, respectively. The random-effects model was applied due to the high heterogeneity (I = 91%, P < .00001). The level of serum ADMA in patients with carotid arteriosclerosis was significantly higher than that in healthy people (SDM = 1.03, 95% CI [0.49, 1.57], P = .0002).
The serum ADMA may be related to ischaemic stroke, and it is a risk factor for carotid atherosclerosis.
探讨成人血清不对称二甲基精氨酸（ADMA）与缺血性中风风险及颈动脉粥样硬化之间的相关性。
我们系统检索了PubMed、EMBASE、Web of Science及其他数据库，查找1980年12月至2019年12月发表的关于血清ADMA与缺血性中风或颈动脉粥样硬化的相关研究。根据Cochrane系统评价标准评估纳入研究的质量。选取缺血性中风组与对照组血清ADMA水平的差异作为效应量（标准化均数差，SMD）。使用Review Manager（V.5.3）进行荟萃分析。
根据纳入标准，筛选后13项研究纳入荟萃分析。9项研究比较了缺血性中风组与健康对照组的ADMA水平，两组分别涉及1315名和880名受试者。由于异质性高（I² = 93%，P <.00001），采用随机效应模型计算合并效应量。缺血性中风患者的血清ADMA水平显著高于健康人（SMD = 0.69，95%CI [0.32, 1.06]，P =.0002）。13篇文章中的7篇比较了颈动脉粥样硬化组与健康对照组的ADMA水平，两组分别有559名和330名受试者。由于异质性高（I² = 91%，P <.00001），应用随机效应模型。颈动脉粥样硬化患者的血清ADMA水平显著高于健康人（SMD = 1.03，95%CI [0.49, 1.57]，P =.0002）。
血清ADMA可能与缺血性中风有关，是颈动脉粥样硬化的一个危险因素。
